340 related articles for article (PubMed ID: 18786751)
1. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
[TBL] [Abstract][Full Text] [Related]
2. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study.
Nanayakkara PW; van Guldener C; ter Wee PM; Scheffer PG; van Ittersum FJ; Twisk JW; Teerlink T; van Dorp W; Stehouwer CD
Arch Intern Med; 2007 Jun; 167(12):1262-70. PubMed ID: 17592099
[TBL] [Abstract][Full Text] [Related]
3. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease.
Nanayakkara PW; Kiefte-de Jong JC; Stehouwer CD; van Ittersum FJ; Olthof MR; Kok RM; Blom HJ; van Guldener C; ter Wee PM; Smulders YM
Nephrol Dial Transplant; 2008 Aug; 23(8):2586-92. PubMed ID: 18287179
[TBL] [Abstract][Full Text] [Related]
4. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
[TBL] [Abstract][Full Text] [Related]
5. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease.
Veringa SJ; Nanayakkara PW; van Ittersum FJ; Vegting IL; van Guldener C; Smulders YM; ter Wee PM; Stehouwer CD
Clin Nephrol; 2012 Oct; 78(4):263-72. PubMed ID: 22981031
[TBL] [Abstract][Full Text] [Related]
6. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
Koyama K; Ito A; Yamamoto J; Nishio T; Kajikuri J; Dohi Y; Ohte N; Sano A; Nakamura H; Kumagai H; Itoh T
Am J Kidney Dis; 2010 Jun; 55(6):1069-78. PubMed ID: 20430500
[TBL] [Abstract][Full Text] [Related]
8. [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients].
Wu CJ; Wang L; Li X; Wang CX; Ma JP; Xia XS
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Dec; 40(12):1003-8. PubMed ID: 23363713
[TBL] [Abstract][Full Text] [Related]
9. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.
Saran R; Novak JE; Desai A; Abdulhayoglu E; Warren JS; Bustami R; Handelman GJ; Barbato D; Weitzel W; D'Alecy LG; Rajagopalan S
Nephrol Dial Transplant; 2003 Nov; 18(11):2415-20. PubMed ID: 14551376
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease.
Panichi V; Mantuano E; Paoletti S; Santi S; Manca Rizza G; Cutrupi S; Pizzini P; Spoto B; Tripepi G; Zoccali C
J Nephrol; 2008; 21(1):38-44. PubMed ID: 18264935
[TBL] [Abstract][Full Text] [Related]
11. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
[TBL] [Abstract][Full Text] [Related]
12. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis.
Potter K; Hankey GJ; Green DJ; Eikelboom J; Jamrozik K; Arnolda LF
BMC Cardiovasc Disord; 2008 Sep; 8():24. PubMed ID: 18803866
[TBL] [Abstract][Full Text] [Related]
13. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
[TBL] [Abstract][Full Text] [Related]
14. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M
JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
van Guldener C; Nanayakkara PW; Stehouwer CD
Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
[TBL] [Abstract][Full Text] [Related]
16. No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk.
Spoelstra-de Man AM; Teerlink T; Brouwer CB; Rauwerda JA; Stehouwer CD; Smulders YM
Clin Endocrinol (Oxf); 2006 May; 64(5):495-501. PubMed ID: 16649966
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
Mann JF; Sheridan P; McQueen MJ; Held C; Arnold JM; Fodor G; Yusuf S; Lonn EM;
Nephrol Dial Transplant; 2008 Feb; 23(2):645-53. PubMed ID: 18003666
[TBL] [Abstract][Full Text] [Related]
18. Supplementation of folic acid and vitamin B₁₂ reduces plasma levels of asymmetric dimethylarginine in patients with acute ischemic stroke.
Xia XS; Li X; Wang L; Wang JZ; Ma JP; Wu CJ
J Clin Neurosci; 2014 Sep; 21(9):1586-90. PubMed ID: 24814858
[TBL] [Abstract][Full Text] [Related]
19. Relationship between L-arginine/asymmetric dimethylarginine, homocysteine, folic acid, vitamin B levels, and coronary artery ectasia.
Koc F; Ardic I; Erdem S; Kalay N; Ozbek K; Yarlioglues M; Ceyhan K; Celik A; Kadi H; Taner A; Sahin S; Onalan O; Kaya MG
Coron Artery Dis; 2010 Dec; 21(8):445-9. PubMed ID: 20861735
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease.
Schmitt B; Wolters M; Kressel G; Hülsmann O; Ströhle A; Kühn-Velten WN; Lichtinghagen R; Bub A; Barth SW; Stichtenoth DO; Hahn A
Atherosclerosis; 2007 Jul; 193(1):168-76. PubMed ID: 16876171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
